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An allosteric interaction controls 
the activation mechanism of SHP2 
tyrosine phosphatase
Massimiliano Anselmi 1,2* & Jochen S. Hub 2
SHP2 is a protein tyrosine phosphatase (PTP) involved in multiple signaling pathways. Mutations 
of SHP2 can result in Noonan syndrome or pediatric malignancies. Inhibition of wild-type SHP2 
represents a novel strategy against several cancers. SHP2 is activated by binding of a phosphopeptide 
to the N-SH2 domain of SHP2, thereby favoring dissociation of the N-SH2 domain and exposing 
the active site on the PTP domain. The conformational transitions controlling ligand affinity and 
PTP dissociation remain poorly understood. Using molecular simulations, we revealed an allosteric 
interaction restraining the N-SH2 domain into a SHP2-activating and a stabilizing state. Only ligands 
selecting for the activating N-SH2 conformation, depending on ligand sequence and binding mode, 
are effective activators. We validate the model of SHP2 activation by rationalizing modified basal 
activity and responsiveness to ligand stimulation of several N-SH2 variants. This study provides 
mechanistic insight into SHP2 activation and may open routes for SHP2 regulation.
Reversible tyrosine phosphorylation is a post-translational modification reciprocally controlled by protein-
tyrosine kinases (PTKs) and phosphatases (PTPs), playing key roles in regulating cell proliferation, differentia-
tion, migration, apoptosis as well as cell–cell communication. Abnormal control of tyrosyl phosphorylation can 
result in various human diseases, including  cancer1,2.
Among PTPs, the SH2 domain-containing phosphatase SHP2 is a regulator of signaling downstream of several 
cell surface receptors, functioning as positive or negative modulator in multiple signaling  pathways3. Notably, 
SHP2 is required for full activation of the RAS/MAPK signaling cascade, and dominantly acting mutations 
of PTPN11, the gene encoding SHP2, cause developmental disorders (i.e., Noonan  syndrome4–7 and Noonan 
syndrome with multiple  lentigines6,8). Somatic mutations in PTPN11 contribute to childhood malignancies, 
among which juvenile myelomonocytic leukemia (JMML) represents the archetypal disorder resulting from 
RAS signaling  upregulation5,9–12. Recent studies suggested SHP2 inhibition as a promising strategy for treating 
a large class of receptor tyrosine kinase-driven  cancers13 and for combating resistance to targeted anticancer 
 therapies14–16. In addition, SHP2 plays a role in Helicobacter pylori-induced gastric cancer mediated by activation 
by the bacterial protein  CagA17, and SHP2 is responsible for the suppression of T-cell activation by programmed 
cell death-1 (PD-1), a receptor hijacked by tumor cells for evading the immune  response18. All these recent 
discoveries indicate SHP2 as an attractive target in future anti-cancer  therapies19–21.
The structure of SHP2 includes two tandemly-arranged Src homology 2 domains, called N-SH2 and C-SH2, 
followed by the catalytic PTP domain, and a C-terminal tail with a still poorly characterized function. The SH2 
domains are recognition elements that allow SHP2 to bind to signaling partners containing a phosphorylated 
tyrosine (pY)22. Crystal structures have revealed an allosteric regulation of SHP2  activity23. Namely, under basal 
conditions, SHP2 is in an autoinhibited state where the blocking loop of the N-SH2 domain occludes the catalytic 
site of the PTP domain. Association of SHP2 to its binding partners via the SH2 domains favors the release of the 
autoinhibitory N-SH2–PTP interactions, rendering the catalytic site accessible to  substrates23–25. Whereas this 
mode of regulation is widely accepted, the molecular mechanisms underlying SHP2 activation, binding partner 
recognition, and allostery of the N-SH2 domain are not well understood.
Atomic structures are available for the autoinhibited, closed state of  SHP223,26, and for the isolated N-SH2 
domain, either with a bound phosphopeptide or in its apo  form24. In addition, a recent structure of the “open” 
state (obtained for the basally active, leukemia-associated E76K mutant) revealed an alternative relative arrange-
ment of N-SH2 and PTP domains, with the active site within the PTP domain exposed to the  solvent25. Accord-
ing to these structures, N-SH2 undergoes a conformational transition between the inactive and active states, 
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leading to a loss of complementarity between the N-SH2 blocking loop and the PTP active site. Previous studies 
hypothesized that the EF loop of N-SH2, as well as the BG loop, play an important role in activation (cf. Fig. 1)27.
Two alternative hypotheses have been put forward for the molecular events leading to functional activation 
of SHP2. First, a “conformational selection” mechanism was proposed based on the observations that (i) the 
crystal structure of the autoinhibited protein shows a completely inaccessible active site, and (ii) even under 
basal conditions in the absence of SH2-binding phosphopeptide ligands, SHP2 exhibits some activity, indicating 
a transient population of open, active conformations. According to this hypothesis, phosphopeptide binding to 
the SH2 domains simply stabilizes the fraction of active SHP2, only after dissociation of N-SH2 from the PTP 
domain has already taken  place7,17,28. Second, according to an “induced fit” model, peptide binding might take 
place in the inactive state of SHP2, triggering the concomitant opening of the  protein29. However, since the 
N-SH2 binding site is closed in the inactive state, phosphopeptide binding to the inactive state would require a 
conformational transition of the N-SH2 domain with respect to the crystal structure. A better understanding of 
SHP2 activation and N-SH2 allostery is the key to clarify how SHP2 function is regulated and how pathogenic 
mutations cause protein dysfunction.
Guided by extensive molecular dynamics (MD) simulations, various types of free energy calculations, and 
enhanced-sampling methods, we present an atomistic model of SHP2 activation based on a concerted confor-
mational rearrangement of the N-SH2 domain upon phosphopeptide binding. According the model, N-SH2 
predominantly adopts two distinct conformations, denoted α- and β-state, where only the α-state is activating, 
whereas the β-state stabilizes the N-SH2–PTP interface. Phosphopeptides may bind to the inactive state, subse-
quently promoting the release of N-SH2 domain from active site; however, the mere phosphopeptide binding is 
not sufficient for SHP2 activation, as only sequences selecting for the α-state are effective activators. Moreover, 
the model rationalizes the effect of certain pathogenetic mutations in terms of altered equilibria between the 
activating and inhibiting N-SH2 conformations.
Results and discussion
Designing an atomistic model of the activation mechanism of SHP2 mediated by the ligand-induced conforma-
tional changes requires understanding of the conformational states of the N-SH2 domain. The N-SH2 domain has 
the two-fold role of blocking the active site of the catalytic domain and recognizing the phosphorylated sequence, 
the latter triggering the structural rearrangements that precede SHP2 opening and activation.
Review of N-SH2 structure and phosphopeptide–N-SH2 interactions. Figure 1 presents two rep-
resentative structures of a phosphopeptide bound to the N-SH2 domain: a crystal  structure24 of the N-SH2 
domain in complex with the SPGEpYVNIEFGS peptide (panel A), and a conformation extracted from the MD 
simulation with the SLNpYIDLDLVK peptide (panel B). Like other SH2 domains, N-SH2 consists of a central 
antiparallel β-sheet, composed of three β-strands denoted βB, βC and βD, flanked by two α-helices denoted αA 
and αB. The peptide binds in an extended conformation to the cleft that is perpendicular to the plane of the 
β-sheet. The phosphotyrosine binding site is delimited by (i) the αA helix, (ii) the BC loop, hereafter referred as 
pY loop, connecting two strands of the central β-sheet, respectively βB and βC, and (iii) the side chains on the 
adjacent face of the β-sheet24.
The key residues involved in the interaction with phosphotyrosine are  Arg32,  Thr42, and  Lys55, lining the 
central β-sheet, and residues  Ser34,  Lys35 and  Ser36, belonging to the pY  loop24. Residues  Ser34,  Thr42 and  Ser36 
Figure 1.  Cartoon representation of the N-SH2 domain in complex with (A) the SPGEpYVNIEFGS peptide 
(crystal structure) 24 and (B) with the SLNpYIDLDLVK peptide, taken from an MD simulation. The peptide 
is shown in cyan, comprising the phosphotyrosine and residues from position + 1 to + 7 relative to the 
phosphotyrosine (see labels). Functionally important loops are highlighted in color: BC “pY” loop (green), 
DE “blocking loop” (light blue), EF loop (magenta), BG loop (deep pink). The phosphotyrosine binds the site 
delimited by the pY loop and the central β-sheet (βB, βC, βD strands). EF and BG loops delimit the “ + 5 site” 
where the peptide residue in position + 5 is settled.
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form hydrogen bonds with the phosphate group, whereas  Arg32 and  Lys55 form salt bridges.  Lys35 contributes to 
stabilizing the phosphate group in the binding site by electrostatic interactions. Regarding the peptide sequence, 
the specificity of peptide–N-SH2 interactions is determined by the peptide residues following immediately after 
the phosphotyrosine, and interacting with the residues of the N-SH2 domain, placed just on the other side of the 
central β-sheet24. Generally, the residues at position + 1 and + 3 relative to the phosphotyrosine are hydrophobic 
side chains, pointing towards the N-SH2 domain, while residues at position + 2 and + 4 are solvent-exposed. 
Residues at position + 2 and + 4 interact with the residues belonging to the BG loop, whose sequence represents 
the principal structural determinant of specificity for the N-SH2 domain. The residue at position + 5 is generally 
inserted into the so-called + 5 site, a pocket formed together by the BG and the EF loops. However, also residues 
further upstream from the phosphotyrosine may interact with N-SH2; for instance, the lysine at positions + 7 
in the example of Fig. 1B favorably interacts with the acidic side chains of residues  Asp64 and  Glu69, belonging 
to the EF loop.
Phosphopeptides retain the native binding mode throughout the simulations. MD simulations 
were initially performed on the isolated N-SH2 domain in solution, complexed with a set of phosphopeptides. 
We considered up to 12 peptides, differing either in length or in sequence and chosen for their high experimental 
binding affinity or chosen to test the influence of sequence variability (Supplementary Fig. S1). During the simu-
lations, all peptides remained in the binding cleft over the entire 1 μs of simulation, in a conformation very simi-
lar to the initial binding mode observed in experimental structures. In Supplementary Fig. S1, the RMS devia-
tion of the most representative MD conformation from the corresponding reference crystal structure is reported 
for each  Cα atom of the phosphopeptide. The least-squares fit was performed considering only the domain back-
bone. Evidently, for all structures the deviation from the experimental binding mode remained below 2–3 Å 
for positions −  1 to + 6 relative to the phosphotyrosine, with the exception of GDKQVEpYLDLDLD, where 
the deviation is below 4 Å. Only the peptide termini exhibit larger RMSD values, indicating weaker structural 
determinants for binding. Overall, these findings demonstrate that, during the whole simulation, the peptides 
are tightly bound to the N-SH2 domain. A detailed analysis of ligand–N-SH2 interactions during these simula-
tions are presented  elsewhere30.
The N-SH2 domain adopts at least two distinct conformations. Whereas the 12 different phos-
phopeptides maintain their usual binding mode during the simulations, the N-SH2 domain can undergo several 
conformational transitions. Starting from the crystal structure, in which the pY loop is tightly wrapped around 
the phosphotyrosine (see Fig. 1A), an opening of the pY loop and the consequent rearrangement of the N-SH2 
domain into another distinct structure was observed in several simulations. To characterize the conformations 
adopted by the N-SH2 domain, principal component analysis (PCA) was applied to the cumulative trajectory 
of all 12 simulations. Hence, the PCA eigenvectors do not necessarily represent the conformational transitions 
undergone by the N-SH2 domain during an individual simulation; instead, they describe the overall conforma-
tional space accessible to the N-SH2 domain.
PCA suggested that the N-SH2 domain adopts two main conformational states, hereafter called α and β. These 
two states were resolved by the first PCA vector, which was representative of almost 40% of the overall domain 
fluctuations. The correlated structural rearrangements detected by the first PCA vector are visualized in Fig. 2A 
by means of the extreme projections onto the vector (see also Fig. 3A), and the related structural rearrangements 
are quantified in Fig. 2E–G. Namely, the α state shown in Fig. 2A (transparent) is characterized by (i) a closed pY 
loop  (Lys35  Cα–Thr42  Cα distance ~ 9 Å), (ii) an increased distance between the ends of two β-strands, βC and βD, 
leading to breaking of three inter-strand hydrogen bonds and spreading of the central β-sheet into a Y-shaped 
structure  (Gly39 C–Asn58 N distance ~ 12 Å), and (iii) the closed + 5 site with a narrow, less accessible cleft  (Tyr66 
 Cα–Leu88  Cα distance ~ 7 Å; see also Fig. 3A, left). The β state shown in Fig. 2A (opaque) is characterized by (i) 
an open pY loop  (Lys35  Cα–Thr42  Cα distance ~ 11 Å), (ii) a closed central β-sheet with parallel β strands  (Gly39 
C–Asn58 N distance ~ 4 Å), and (iii) an open + 5 site with an accessible cleft  (Tyr66  Cα–Leu88  Cα distance ~ 12 Å, 
see also Fig. 3A, right).
A correlation analysis showed that the conformation adopted by the pY loop is strictly coupled to the spread 
of the central β-sheet (Fig. 2B, correlation R = − 0.82). Structurally, this coupling is imposed by a competition 
between (a) inter-strand hydrogen bonds (one between  Gly39–Asn58 and two between  Phe40–Ile56) of the central 
β-sheet and (b) hydrogen bonds of  Ser34 and  Ser36 of the pY loop with the phosphate group of the phosphotyros-
ine. Namely, closed inter-strand hydrogen bonds lock the pY loop in an upright, open position, whereas broken 
inter-strand hydrogen bonds render the pY loop sufficiently flexible for reaching a closed conformation in tight 
contact with the phosphotyrosine.
The correlations between the spread of the central β-sheet and pY loop (Fig. 2C, R = − 0.73) as well as between 
the pY loop and the opening/closure of the + 5 site (Fig. 2D, R = 0.64) are slightly weaker yet clearly detectable. 
The latter correlation represents a potential mechanism for modulating the conformational rearrangement of 
the N-SH2 domain, through the recognition of a particular peptide sequence at the + 5 site, as analyzed in the 
following in detail.
The conformational changes of pY loop and of the + 5 site are highly concerted. Our simula-
tions suggest a coupling between the pY loop and the + 5 site, revealing an allosteric interaction for controlling 
the state of the pY loop through binding of a specific amino acid sequences at the + 5 site (Fig. 2D). To analyze 
the coupling during simulations with different peptides, we split the PCA vector into two subvectors (comprising 
 Ser34–Phe41 and  Gln57–Glu97 backbone respectively) that describe the motion either of the pY loop or of the + 5 
site. In principle, projections on these two subvectors could characterize four conformational states given by the 
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two possible states of the pY loop times two possible states of the + 5 site (four shaded areas in each panels of 
Fig. 3B,C). The two additional states, relative to the α and β states characterized above, would be given by (i) a 
closed pY loop with an open + 5 site (typical for the isolated N-SH2 domain in crystal environment) and (ii) an 
open pY loop with a closed + 5 site (Fig. 3B,C, white areas in panels).
As reported in Fig. 3B,C, a correlation between the pY site and the + 5 site is observed in all simulations, 
where most peptides strictly select for either the α or for the β state (Fig. 3B,C, blue/green areas). In other words, 
when the pY site is closed, the + 5 site is mostly closed (β state); when the pY site is open, the + 5 site is always 
open (α state). Consequently, a conformational change at the pY site is accompanied by a concerted conforma-
tional change at the + 5 site, spanning ~ 20 Å across the N-SH2 domain. These results support the presence of 
an allosteric mechanism that couples two binding sites with different physicochemical properties: the pY site, 
characterized by a high affinity for phosphotyrosine but lacking specificity, and the + 5 site, whose role is to induce 
specificity in the binding of different amino acid sequences.
The phosphopeptide binding mode and sequence play important roles in selecting the N-SH2 
domain conformation. The equilibrium MD simulations showed that each peptide may induce the 
N-SH2 domain to populate mostly one among the two conformations, and the simulations revealed a correla-
tion between the pY and + 5 sites. However, it is unlikely that each individual simulation may explore all pos-
sible binding modes of a phosphopeptide within 1 μs of simulation time. Indeed, the interconversion between 
binding modes would first involve a weakening of peptide–N-SH2 interactions, before the required side chain 
and backbone reorientations may occur. Consequently, the equilibrium MD simulations were insufficient for 
unambiguously deciding whether a specific peptide sequence selects for the α or the β state.
However, the simulations did reveal how specific binding modes may lock N-SH2 in the α or β state. Fig-
ure 3C compares the simulation of the SLNpYIDLDLVK peptide with simulations of three peptide analogues 
with modifications at positions + 6, + 7 and + 8, thereby adopting different polarities at the capped carboxy ter-
minus. These subtle differences in the sequence affected the orientation of the residue in position + 5. In case 
of SLNpYIDLDLVK and SLNpYIDLDLVND, the leucine side chain at position + 5 was exposed to the solvent, 
thereby allowing closure of the + 5 site and consequently the population of the α state. In contrast, in case of 
SLNpYIDLDLV and SLNpYIDLDLVKD, the leucine side chain points towards the binding cleft, keeping the + 5 
site open and the N-SH2 domain in the β state.
To investigate in more detail the role of the residue at the + 5 site in imposing the N-SH2 conformation, we 
carried out a large set of additional free energy calculations using non-equilibrium transitions and Crooks Fluc-
tuation  Theorem31,32. To this end, we computed the change of preference of the ligand/N-SH2 complex for the α 
or the β state upon introducing a mutation in the ligand, according the thermodynamic cycle reported in Sup-
plementary Fig. S2. Supplementary Fig. S3 presents the computed ΔΔG values for the ligands  SLNpYIDLDL+5VK 
and  SPGEpYVNIEF+5GS for all possible mutations (except proline) at position + 5 and, as a control, at posi-
tion + 6. Positive ΔΔG indicates an augmented preference for the α state, and a negative ΔΔG an augmented 
preference for the β state. Evidently, mutations at the + 5 position modulate the α-versus-β preference by up to 
Figure 2.  Conformational states and correlations revealed by the first PCA vector. (A) Conformational 
transition from β (opaque) to α (transparent), representing the two main conformational states adopted by 
the N-SH2 domain, here visualized as the extreme projections onto the first PCA vector. The residues used to 
quantify the β-sheet spread, the pY loop opening, and the + 5 site opening are highlighted in red, green, and 
blue, respectively. (B–D) Correlation between the β-sheet spread, pY loop opening, and + 5 site opening, as 
taken from microsecond simulations of N-SH2 bound to 12 different peptides. The distances were defined as 
described in the main text. (E–G) Correlation between the projection η1 onto the first PCA vector and β-sheet 
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14 kJ/mol, whereas mutations at the + 6 position have a much smaller effect. Generally, bulky hydrophobic ami-
noacids at + 5 such as Phe, Leu, Ile seem to stabilize the β state (Supplementary Fig. S4), whereas substitutions 
with bulky polar amino acids such as Asp, Glu, Arg, Asn, or Gln seem to favor the α state (Supplementary Fig. S5), 
although exceptions exist. These trends in stabilizing α versus β, as derived from the free energy calculations, are 
well confirmed by additional free simulations (Supplementary Figs. S4 and S5).
Taken together, these data show that the preference for one of the two alternative conformations, α or β, 
depends not only on the particular peptide sequence but also on the binding mode adopted by the ligand. In 
particular, both the polarity and the spatial orientation of peptide residue at the + 5 site emerge as key determi-
nants for the N-SH2 conformation. Other residues might control the α-β equilibrium indirectly by influencing 
the peptide binding mode.
Free-energy calculations confirm that the ligand residue at the + 5 site is a key determinant for 
the preference N-SH2 for the α or β state. To overcome sampling problems of unbiased MD simula-
tions and to rationalize the preference for the α or β states in energetic terms, we computed the free energy 
profile of the α–β conformational transition using umbrella sampling. Here, we used the distance between the 
central β-strands as the reaction coordinate because (i) this distance is strongly correlated with the α–β transi-
tion (see Fig. 2B–E) (ii) pulling along a center-of-mass distance may be less prone to sampling problems as 
compared to pulling along a collective PCA vector.
The conformational equilibrium between the α and β states is determined by a balance of different energetic 
contributions: (i) the intermolecular interactions between the ligand and the N-SH2 domain, and (ii) the intra-
molecular interactions between the residues of N-SH2, as rationalized for three typical binding modes:
Figure 3.  (A) Cartoon representation of the two conformations, α (left) and β (right), adopted by the N-SH2 
domain, and shown as the extreme projections onto the first PCA vector. From the first PCA vector, two 
subsectors were selected, describing the motions of the pY loop  (Ser34–Phe41, red cartoon) and of the + 5 site 
 (Gln57–Glu97, blue cartoon), respectively. The residues used for defining the + 5 site comprise the end of the 
βD strand, the DE “blocking” loop, the EF loop, the αB helix and the BG loop. (B,C) Projection of N-SH2 
trajectories with different bound peptides (subplot titles) projected onto the PCA subvectors of the pY loop 
(abscissa) and of the + 5 site (ordinate). The region corresponding to the α state (pY loop closed, + 5 site closed) 
is shaded in green, the region of the β state (pY loop open, + 5 site open) is shaded in blue.
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• In absence of a ligand (Fig. 4A), the β state represents the free-energy minimum, presumably favored by 
the formation of inter-strand H-bonds between the closed central β-sheet. In turn, increased free energy is 
required for spreading the β-strands into a Y-shaped structure, so that adopting the α state is unfavorable.
• In presence of a truncated ligand, such as SPGEpYVNI (Fig. 4B), which contains a phosphotyrosine but lacks 
the residues flanking the + 5 site, the α state is the free-energy minimum. In this case, the pY loop–phosphate 
interactions prevail over inter-strand H-bonds of the central β-sheets, leading to closure of the pY loop and 
opening of the β-sheets.
• With the ligand SPGEpYVNIEFGS, the β state is the free-energy minimum (Fig. 4C). Here, a bulky pheny-
lalanine at position + 5 occupies the cleft of the + 5 site, thereby keeping the + 5 site open. This conformation 
stabilizes the central β-sheet, aiding the inter-strand H-bonds of the β-sheet to prevail over the pY loop–
phosphate H-bonds. Consequently, β-sheets close and pY-loop opens.
The free energy profiles confirm that a subtle balance between (i) ligand/N-SH2 interactions and (ii) intra-
domain interactions within N-SH2 determine the conformation of N-SH2. The ligand residue at the + 5 position 
plays a key role in imposing the α versus the β state. However, because the side chain at ligand position + 5 may 
adopt different orientations relative to the + 5 site (towards the cleft or solvent-exposed), not only the type of side 
chain, but also the binding mode of the overall ligand may influence the N-SH2 conformation.
The N-SH2 domain populates the β state in the autoinhibited state of SHP2. One of the main 
features that distinguishes the α state from β, namely the spread of the central β-strands, is also revealed by 
comparing the crystallographic structures of the autoinhibited conformation of SHP2 with those of the N-SH2 
domain bound to a phosphopeptide. Supplementary Table  S1 reports the distance between the two central 
β-strands, βC and βD, for each crystal structure. Evidently, in the autoinhibited conformation of SHP2, the dis-
tance between the β-strands is small (3.7–4.0 Å) indicative of closed β-sheets23,26. Hence, N-SH2 bound to PTP 
adopts a conformation similar to the β state observed in simulations. In contrast, when N-SH2 is complexed 
with a phosphopeptide, this distance is greater (~ 7–8 Å) indicative of open β-sheets, a peculiarity of the α  state24.
Figure 4.  Free energy profiles of the opening of the central β-sheet for the N-SH2 domain in apo state (no 
ligand), bound to a truncated peptide (SPGEpYVNI), or bound to a full-length peptide (SPGEpYVNIEFGS). 
The opening of the central β-sheet was quantified as the distance between the backbone N and C atoms of 
residues  Gly39 and  Asn58, respectively.
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Whereas the central β-strands of N-SH2 have clearly taken the β-state in crystal structures of autoinhibited 
SHP2, as reported in the previous paragraph, the structures of the pY loop and of the + 5 site have been crystallo-
graphically less well defined. The pY loop was typically modeled with a partly open conformation, corresponding 
to an intermediate conformation between the α- and β-states described here (2SHP, 4DGP)23,26. However, the 
electron densities at the pY loop were much lower compared to the density of the nearby β-strands (e.g. 2SHP, 
4DGP, 4GWF)23,26, indicating increased disorder of the pY loop. Further, the partially closed pY loop might have 
been stabilized by crystal contacts (e.g. 2SHP, 4DGP)23,26 and by a buffer phosphate bound to the phosphotyros-
ine binding site, as modeled by the 5EHP  structure33. Indeed, during the MD simulations with CHARMM36m 
or different Amber force fields, the pY loop of autoinhibited SHP2 reproducibly opened up, taking the open 
pY loop conformation of the β-state (Supplementary Fig. S6). Likewise, the electron density of the BG loop, 
which forms the pocket of the + 5 site together with the EF loop, was poorly defined in several SHP2 crystals 
and, consequently, only partly modeled against the data by several authors (5EHP, 4GWF)33. Again, during free 
simulations of apo SHP2 in solution, we repeatedly observed a complete opening of the cleft at the + 5 site (Sup-
plementary Fig. S6B), consistent with the β state. Taken together, crystallographic data unambiguously showed 
that that central β-strands of N-SH2 take the β-state in the autoinhibited state of SHP2. For the pY and + 5 site, 
crystallographic data is more ambiguous and, hence, simulations presented here were needed to reveal that also 
the pY and + 5 site take the β-state in autoinhibited SHP2.
The α state promotes SHP2 opening and activation. Based on the observation that the β state is 
found in association with the autoinhibited SHP2, whereas in crystal structures, the isolated, peptide-bound 
N-SH2 structure resembles the α state, we hypothesized that the α state represents an activating state. Accord-
ing to this model, binding of an activating phosphopeptide would trigger the first steps of SHP2 activation 
by switching the N-SH2 domain towards the α conformation and, subsequently, weakening the interactions 
between the blocking loop and the catalytic site.
To test this model, we used umbrella sampling to compute the free energy profiles of SHP2 activation with 
the N-SH2 domain restrained either to the α or to the β state. Here, the restraint to α or β was implemented by 
restraining a single principal component, while leaving all other degrees of freedom unbiased, hence representing 
only a mild restraint (cf. “Methods”). As a reaction coordinate for SHP2 activation, we used the center-of-mass 
distance between the backbone atoms of blocking loop and the catalytic PTP loop. Upon pulling the simulation 
system along this coordinate, the N-SH2 domain moved from its position in the autoinhibited state (Fig. 5A) 
to a different position on the PTP surface (Fig. 5B), typically by sliding over the PTP surface. The final position 
of N-SH2 differed among independent simulation runs, indicative of a large accessible conformational space of 
activated SHP2 (Supplementary Fig. S7).
In agreement with the model, we found that the N-SH2 state strongly influences the free energy of activation 
(Fig. 5C). Namely, according to the free energy profile for the N-SH2 domain restrained to the β state, a high 
free energy penalty is associated with SHP2 activation, indicating that the β state favors a stable autoinhibited 
SHP2 conformation (Fig. 5C, blue line). In contrast, upon restraining N-SH2 in the α state, SHP2 activation is 
associated with only a small barrier, and the active state represented the free-energy minimum (Fig. 5C, green 
line). To exclude that the choice of the reaction coordinate influences these findings, we computed a second set 
of free energy profiles along the distance between the  Cα atoms of residues  Asp61 and  Ala461, representing central 
residues of the blocking loop and catalytic PTP loop, respectively. These profiles were qualitatively similar to the 
first set of profiles (Supplementary Fig. S8). Taken together, with both the reaction coordinates, we consistently 
obtained greatly increased free energy for activation in the β state as compared to the α state, corroborating that 
the α state destabilizes the N-SH2/PTP interface, thereby promoting activation.
Figure 5.  (A) In the autoinhibited structure of SHP2, the N-SH2 domain (cyan cartoon) blocks the catalytic 
site (red) of the PTP domain (pink) with the blocking loop (blue). The N-SH2 domain is connected to PTP 
in tandem with the homologous C-SH2 domain (orange). (B) Open and active structure obtained by pulling 
simulation coupled with simulated tempering, using the color code of (A). (C) Free energy profiles of SHP2 
opening with the N-SH2 restrained to the α state (green line) or to the β state (blue line). The free energy 
calculations were performed using CHARMM36m force field. The distance between the blocking loop and the 
catalytic PTP loop, in terms of distance between the backbone centers-of-mass of residues 60–62 and residues 
460–462, was taken as reaction coordinate.
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Amino acid substitutions at codon 42: basal activity and response to ligand stimulation are 
rationalized with altered conformational selection between the α and β state. Many patho-
genic mutations of SHP2 cluster at the N-SH2/PTP interface, where they may destabilize the N-SH2/PTP inter-
actions, causing constitutive activation of  SHP229. However, certain pathogenic mutations seem to have more 
subtle, allosteric effects, since their impact on SHP2 function cannot be rationalized by mere steric effects. Here, 
we study such mutations to test our proposed model of SHP2 activation. A typical example is the Noonan Syn-
drome (NS)-causing Thr42Ala substitution that replaces a conserved threonine in the central β-sheet. Because 
 Thr42 forms an H-bond with the phosphotyrosine in wild-type (wt) N-SH2, one might expect that  Thr42 con-
tributes to the stability of the N-SH2/phosphopeptide complex. However the substitution with alanine leads to 
an increase in phosphopeptide binding  affinity6, as documented by the dramatically enhanced catalytic activity 
of the  SHP2A42 mutant following stimulation with a bisphosphoryl tyrosine-based activation motif (BTAM) 
 peptide6,28.
Notably, among all possible mutants arising from single base changes in codon 42, all but two SHP2 mutants 
exhibit a basal catalytic activity comparable to wild-type SHP2. The exceptions are  SHP2P42 that showed a three-
fold increase, and  SHP2I42 that showed a 50%  increase6. Upon BTAM peptide stimulation, mutants not associated 
with NS were either responsive  (SHP2S42,  SHP2R42), with a variable increase of the catalytic activity respect to 
the basal condition, or unresponsive  (SHP2P42,  SHP2I42,  SHP2K42). Relative to the wild-type protein,  SHP2S42 
exhibits a 50% higher stimulated activity, whereas in  SHP2R42 the stimulated activity was significantly  lower6. 
Surprisingly, despite the different range of catalytic activities exhibited by these mutants, the binding affinities 
were only moderately affected, with the exception of the above-mentioned  SHP2A42 6.
These modifications of basal activity and responsiveness to peptide stimulation cannot be easily explained by 
perturbed interaction between residue 42 and the phosphotyrosine. Previous simulations, which showed reduced 
fluctuations of the pY loop in the Thr42Ala mutant did not reveal a molecular mechanism of the mutation  effects6. 
Therefore, we hypothesized that the overall change of the catalytic activity might derive from a combination 
of two mechanisms: (i) the perturbation of phosphotyrosine interaction upon amino acid substitution, which 
may affect both the α and the β state, and (ii) the shift of the equilibrium between the activating α state and 
the stabilizing β state, which may arise from the replacement of the conserved threonine at the central β-sheet.
We computed the free energy profile for the opening of the central β-sheet, as required for the β-to-α transi-
tion, for wild-type N-SH2 and for various mutants of the domain in absence of phosphopeptide (Fig. 6A,B). 
Remarkably, the Thr42Ile mutant greatly stabilized an open β-sheet conformation corresponding to the activating 
α state, which is compatible with the experimentally observed increased basal activity of  SHP2I42 (Fig. 6B, green 
solid line)6. All other simulated mutants had a smaller effect on the conformation of the central β-sheet, in line 
with a basal activity of those mutants similar to the wild type (Fig. 6B). These findings support the hypothesis 
that mutations may modify the basal activity of SHP2 by shifting the conformational equilibrium of apo N-SH2. 
In addition, the simulations corroborate our hypothesis that the α state, as stabilized by the Thr42Ile mutant, is 
indeed an activating state.
Next, we evaluated whether mutations at codon 42 may modulate the binding affinity of a peptide to N-SH2 
either in the activation α state or in the stabilizing β state. Because it is difficult to sample a complete ligand 
binding process or the α–β transition in the presence of a peptide, we used thermodynamic cycles and alchemi-
cal free-energy calculations based on Crooks  Theorem31,32. Accordingly, we here computed the free energies for 
alchemically transforming  Thr42 to amino acids Ser, Ala, Ile, Lys, or Arg, either in presence (denoted ΔGP-P*[bou]) 
or absence (ΔGP-P*[unb]) of a bound reference peptide SLNpYIDLDLVK. Using a thermodynamic cycle, the 
difference between these two ΔG-values, denoted ΔΔG, yields the change in peptide binding affinity upon 
introducing the mutation. Critically, because these calculations were carried out with N-SH2 restrained either 
in the α or in the β state, the computed ΔΔG(α) and ΔΔG(β) values show whether a  Thr42 mutation (de)stabilizes 
ligand binding to the α state, to the β state, or to both.
We found that the Thr42Ile, Thr42Lys, Thr42Arg substitutions greatly affect the affinity of the peptide to the 
activating α state, as evident from large positive ΔΔG(α) values in a range of tens of kilojoule per mole (Fig. 6C, 
red bars). However, the same mutations only moderately affect the peptide affinity to the β state, as shown by 
ΔΔG(β) the range of only a few kilojoules per mole (Fig. 6C, blue bars). Hence, upon introducing these amino 
acid changes, the peptide may still bind to SHP2, but the α–β equilibrium is greatly shifted towards β in the 
ligand-bound state [because ΔΔG(β) « ΔΔG(α)]. In other words, for these mutants, ligand binding is favorable 
only in the autoinhibited state of SHP2, thereby locking N-SH2 in the stabilizing β state. Therefore, the mutations 
Thr42Ile and Thr42Lys render SHP2 completely unresponsive to ligand stimulation (ΔΔG(α) values of + 43 kJ/
mol or + 21 kJ/mol, Fig. 6C), in qualitative agreement with the experimental  findings6. The substitution Thr42Arg 
with a ΔΔG(α) value of + 13 kJ/mol only moderately destabilizes the α state, thereby rendering the mutant less 
responsive than the wild type, qualitatively in line with experimental  data6.
Structurally, the perturbations of the affinity to the α and β states in Thr42Ile, Thr42Lys and Thr42Arg SHP2 
mutants may be rationalized considering that any substitution to a larger side chain impedes the formation of the 
directed hydrogen bonds involved in the closed pY loop. In contrast, in the β state, the substitution with isoleu-
cine does not significantly affect the salt bridges with domain residues  Arg32 and  Lys55, and the steric hindrance 
of arginine and lysine is balanced by the new electrostatic interaction with the phosphate group.
The ΔΔG values for the Thr42Ser and Thr42Ala substitutions are qualitatively different compared to the 
Thr42Ile, Thr42Lys and Thr42Arg (Fig. 6C). For Thr42Ser and Thr42Ala, the respective ΔΔG(α) and ΔΔG(β) 
are similar, suggesting that ligand binding does not lock N-SH2 in the stabilizing β state but instead ligand 
binding still allows population of the activating α state. Consequently, Thr42Ser and Thr42Ala are responsive to 
ligand stimulation, again in qualitative agreement with the  experiment6. Taken together, both the basal activity 
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of mutants at codon 42 as well as their response to ligand stimulation correlate with modified α–β equilibria 
revealed by the free-energy calculations, corroboration that α is an activating state.
The increased peptide affinity of Thr42Ala might be associated with a modified α–β equilib-
rium. In line with the available experimental observations, Thr42Ile, Thr42Lys and Thr42Arg have only a 
small effect on the overall ligand affinity, as evident from ΔΔG(β) values close to zero; instead, these mutations 
merely shift the equilibrium of the peptide-bound N-SH2 towards the β state (see above). Rationalizing experi-
mental ligand affinities of Thr42Ala and Thr42Ser is, however, more difficult in the light of the ΔΔG values. 
Namely, for the Thr42Ala N-SH2, we found slightly positive ΔΔG values for both the α and the β state, indicating 
a reduced ligand affinity (Fig. 6C). For Thr42Ser, we found slightly negative ΔΔG values, indicating an increased 
ligand affinity. These ΔΔG values are structurally expected because Thr42Ala leads to a loss of the H-bond of 
residue 42 with the phosphotyrosine, whereas this H-bond is maintained in Thr42Ser. However, at first sight, 
these values seem to contradict surface plasmon resonance experiments that reported an increased ligand affin-
ity to Thr42Ala and an unmodified affinity to  Thr42Ser6.
We hypothesize that the structurally unexpected, but experimentally found, increased affinity to Thr42Ala 
may be rationalized by a modified α–β equilibrium of apo N-SH2. The free energy profiles for the opening of 
the central β-sheet suggest that a substitution of Thr42 with an aliphatic residue, such as alanine or isoleucine, 
renders the N-SH2 domain more prone than the wild type to spread the β-strands into a Y-shaped structure and, 
hence, to adopt the α state (Fig. 6B, compare cyan/green lines with red line). We expect that such increased popu-
lation of the α state would facilitate peptide binding because, only in the α state, the pY loop is tightly wrapped 
around the phosphotyrosine, thereby forming strong polar interactions with the peptide. To validate this model 
of Thr42Ala affinity in a quantitative manner, calculations of the absolute peptide binding affinity, possibly with 
N-SH2 restrained to the α or to the β state, as well as structural studies will be required in the future. However, 
Figure 6.  (A) Cartoon representation of N-SH2, wild type and  Thr42 mutants (A42, S42, I42, K42, R42), sorted 
according the size of the sidechain (Ala < Ser < Thr < Ile < Lys < Arg). (B) Free energy profile for the opening 
of the central β-sheet in absence of a ligand, in wild type and T42 mutants, as a function of the N–C distance 
between the residues  Gly39 and  Asn58. Statistical errors were < 2 kJ/mol (not shown for clarity). (C) ΔΔG of 
binding of the ligand SLNpYIDLDLVK to the T42 mutants, relative to the wild-type, calculated for the N-SH2 
domain in α or in β state.
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considering that modulations of conformational equilibria are widely adopted by enzymes to control ligand 
 affinity34, a modified α–β equilibrium is a plausible mechanism of the increased peptide affinity of Thr42Ala.
Conclusions
We presented an atomistic mechanism for activation of SHP2, mediated by ligand-induced conformational 
changes of the N-SH2 domain. Extensive simulations showed that N-SH2 in solution adopts two distinct con-
formations, denoted α and β. The α and β states exhibit different structures of the central β-sheet and of two 
ligand interaction sites, which are responsible respectively for the binding of the phosphotyrosine (pY site) and 
for recognizing peptide residues downstream of the phosphotyrosine (+ 5 site).
The simulations revealed an allosteric interaction between the pY and + 5 sites, mediated by the conformation 
of the central β-sheet: when the pY site is closed, the + 5 site is mostly closed, with the central β-sheet arrang-
ing in a Y-shaped conformation; when the pY site is open, the + 5 site is always open, with the central β-sheet 
retaining parallel β-strands.
In absence of a ligand, the N-SH2 domain remains in the β state, both in its isolated form and in the auto-
inhibited structure of SHP2. Peptide binding may either lock the N-SH2 domain in the β state or trigger the 
transition to the α state, depending on the sequence and the binding mode of the peptide around the + 5 site. 
Hence, the allosteric interaction provides a means for controlling the conformations of both the pY site and of 
the central β-sheet by specific peptide sequences and peptide binding modes at the + 5 site.
A ligand-induced transition from the β to the α state has two consequences; (i) the phosphotyrosine is 
bound more tightly because only in the α state the pY loop is sufficiently flexible in order to fully close onto the 
phosphate group, thereby forming stronger polar interactions. This mechanism provides a means for control-
ling ligand affinity via the conformation at the + 5 site; (ii) in SHP2, with N-SH2 in the α state with a Y-shaped 
central β-sheet, interactions between the N-SH2 domain and the catalytic PTP domain are weakened, thereby 
facilitating the dissociation of N-SH2 and hence the activation of SHP2. According to this model, peptide bind-
ing to N-SH2 is necessary but not sufficient for SHP2 activation as only those peptides that select for the α state 
are activating (Fig. 7).
The model of SHP2 activation was further validated by rationalizing the effects of amino acid substitutions 
of  Thr42 in terms of altered equilibria between the α and the β state. We found that  Thr42 mutations may shift 
the α–β equilibrium of N-SH2 both in the apo form and in contact with ligands, thereby modulating the basal 
activity (Thr42Ile) or the responsiveness to ligand stimulation, in qualitative agreement with experimental data. 
We further hypothesized that an altered α–β equilibrium may underlie the structurally unexpected increased 
peptide affinity of the Thr42Ala mutant.
Figure 7.  Simplified scheme of SHP2 activation, triggered by a ligand binding-induced conformational 
transition of the N-SH2 domain. In the apo form, in absence of a peptide, N-SH2 adopts the β state, leaving 
SHP2 mostly a closed autoinhibited structure (left panel). Binding of certain peptides may lock N-SH2 in the 
β state, stabilizing the autoinhibited conformation of SHP2 (upper panel). SHP2 activation proceeds only if the 
peptide promotes the transition of the N-SH2 domain towards the α state, leading to a Y-shaped central β-sheet, 
thereby weakening the N-SH2–PTP interactions (lower panel). N-SH2 dissociates from PTP, thereby exposing 
the active site of PTP to the solvent (red hexagon, right panel).
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Understanding of the activation mechanism of SHP2 also forms the basis to a mechanistic understanding of 
SHP2 inhibition by small molecules or peptide mimics and, consequently, such understanding may guide the 
development of new therapeutic options. Specifically, our finding that the selection of particular binding modes 
leads to the activation, rather than mere binding of the effector, opens novel strategies for SHP2 regulation. As 
such, we hope that the allosteric activation mechanism of SHP2 proposed here will support ongoing efforts 
against genetic disorders involving  SHP213,35–37.
Methods
MD simulations of the N-SH2 domain complexed with different phosphopeptides. Molecu-
lar dynamics simulations were performed on the isolated N-SH2 domain in solution, complexed with a set of 
phosphopeptides, with natural or synthetic sequence, comprising SLNpYIDLDLVK (IRS-1 pY1172)38, IEEp-
YTEMMPAA (IRS-1 pY546)39, QVEpYLDLDLD (Gab1 pY627)40, SVLpYTAVQPNE (PDGFR-β pY1009)39, 
 AALNpYAQLMFP41,  RLNpYAQLWHR41, SPGEpYVNIEFGS (IRS-1 pY895)39,  VLpYMQPLNGRK42, and their 
analogs. The initial atomic coordinates were derived from crystallographic structures (Supplementary Table S2). 
For some peptides (e.g., SPGEpYVNIEFGS) the sequence in the simulation exactly matched the original 
sequence, and the crystal structure has been used without any modification. For other peptides (e.g., SLNpY-
IDLDLVK), the crystal structure with the highest peptide sequence similarity was chosen, and the structure was 
edited by means of Molecular Operative Environment (MOE)43, followed by a conformational analysis and a 
local energy minimization with side chain repacking, yielding a reasonable binding pose for all peptides (Supple-
mentary Table S2). The termini of peptides were capped by acetyl and amide groups. N-SH2 domains in simula-
tion comprised the residues from position 3 to 103. Each protein molecule was put at the center of a dodeca-
hedron box, large enough to contain the domain and at least 0.9 nm of solvent on all sides. Thus depending 
the specific length and charge of the peptides, the protein was solvated with ~ 4400–6700 explicit TIP3P water 
 molecules44, and up to 6  Na+ ions were added to neutralize the system. All MD simulations were performed with 
the GROMACS software  package45, using AMBER99SB force field if not stated  otherwise46, augmented with 
parm99 data set for  phosphotyrosine47. Long range electrostatic interactions were calculated with the particle-
mesh Ewald (PME)  approach48. A cutoff of 1.2 nm was applied to the direct-space Coulomb and Lennard–Jones 
interactions. Bond lengths and angles of water molecules were constrained with the SETTLE  algorithm49, and all 
other bonds were constrained with  LINCS50, The pressure was set to 1 bar using the weak-coupling  barostat51. 
The temperature was controlled at 300 K using velocity rescaling with a stochastic  term52. For all systems, the 
solvent was relaxed by energy minimization followed by 100 ps of MD at 300 K, while restraining protein coor-
dinates with a harmonic potential. The systems were then minimized without restraints and their temperature 
thermalized to 300 K in 10 ns, in a stepwise manner. Finally, production simulations of 1 μs were performed.
Principal component analysis (PCA) of the N-SH2 domain dynamics. PCA was performed on a 
cumulative trajectory of all simulations of the N-SH2 domain, after removing ligand coordinates. The structures 
were superimposed by a least-squares fit on the backbone considering only the residues with small root mean-
squared fluctuation, representing the relatively rigid core of the domain. The core was defined by the sequence 
ranges  Phe7–Pro33,  Asp40–Arg47,  Ala50–Asn58,  Asp61–Leu65,  Phe71–Tyr81,  Leu88–Glu90,  Val95–Pro101. This proce-
dure avoids that the fits are influenced by large fluctuations of loops and termini. The covariance matrix was built 
using backbone atoms of residues  Trp6 to  Pro101, excluding the flexible termini.
From the PCA vector v for residues 6–101, subvectors were taken containing only the coordinates for residues 
 Ser34–Phe41 and  Gln57–Glu97. Technically, these subvectors were generated using PCA with only the respective 
subsets of atoms, applied to a trajectory which had been projected onto the full-length PCA vector v.
MD simulations of the activation of SHP2, with N-SH2 restrained into the α or β state. The 
initial coordinates of SHP2 were taken from the autoinhibited conformation (2SHP)23. The protein was posi-
tioned at the center of a dodecahedral box, large enough to contain the protein and at least 0.9 nm of solvent on 
all sides, and solvated with ~ 23,000 explicit water molecules and three  Na+ ions. Because certain Amber force 
fields in conjunction with TIP3P have been reported to overstabilize protein–protein  contacts53, we used the 
CHARMM36m force field for simulations of SHP2  activation54. The structure was minimized and thermalized 
to 300 K using the procedure described above. A simulation of 1 μs was performed to ensure a well equilibrated 
autoinhibited structure in solution (Supplementary Fig. S6). Next, the N-SH2 domain of SHP2 was restrained in 
one of two distinct states (denoted as α- and β-state) using a harmonic restraint on a single principal component 
of  Cα atoms from residue  Trp6 to  Pro101 (k = 1000 kJ/mol nm2). All other degrees of freedom were unrestrained. 
This procedure allowed considerable conformational sampling while maintaining the N-SH2 domain in a par-
ticular conformational substate. The restraining potential was introduced gradually, while the temperature was 
increased from 50 to 300 K in 5 ns and then maintained constant for another 5 ns. Such a procedure allowed to 
minimize the perturbation at the interface between PTP and N-SH2 during the conversion of the N-SH2 domain 
from the β- to the α-state (Supplementary Fig. S9).
N-SH2 was pulled away from PTP using 600 ns pulling simulations at constant pull  velocity55,56. Here, two 
sets of simulations were performed using two distinct reaction coordinates (RCs), respectively. First,  RC1 was 
defined as the center-of-mass distance between the blocking loop (residues 60–62) and the catalytic PTP loop 
(residues 460–462).  RC1 was pulled from 0.73 to 2.15 nm. Second,  RC2 was defined as the distance between the 
 Cα atoms of  Asp61 and  Ala461.  RC2 was pulled from 0.55 to 1.97 nm. Only for free energy calculations along  RC1, 
hydrogen atoms were described as virtual sites. To obtain statistically independent pathways for SHP2 opening, 
three pulling simulations were carried out for each reaction coordinate, each restrained either in the α- or in the 
β-state (12 simulations in total).
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To further improve the conformation sampling during these pulling simulations and to obtain more inde-
pendent starting frames for umbrella sampling (see below), we coupled the pulling simulations with simulated 
 tempering57. In line with previous  studies57,58, simulated tempering simulations were carried out at constant 
volume. For simulated tempering, temperature steps of 5 K between 300 and 400 K were applied. Temperature 
changes were controlled according to the Metropolis  algorithm59 to obtain canonical ensembles at all tempera-
tures. The initial weights were chosen following Park and  Pande58. Temperature transitions were attempted every 
1 ps, and the weights were updated throughout the whole simulation according to the Wang-Landau adaptive 
weighting  scheme60. The pull force constant was set to 10,000 kJ/mol   nm2, whereas the reference position was 
changed with a velocity of 2.5 × 10–6 nm/ps.
Free energy profiles of the SHP2 opening. The free energy profiles for the opening of SHP2 were 
obtained using umbrella sampling and the weighted histogram analysis method (WHAM)61,62. Four free energy 
profiles were computed: along  RC1 or along  RC2, and with N-SH2 either restrained in the α- or in the β-state. For 
each profile, 72 windows were used. Initial configurations for umbrella sampling were taken from the simulated 
tempering pulling simulations by means of a cluster analysis, thereby ensuring that the umbrella simulations 
were triggered from the most representative conformations. Accordingly, the configurations were collected from 
the sub-ensemble at 300 K, divided in 72 groups on the base of the umbrella window interval they belong, and 
clustered using the GROMOS clustering  method63. The clustering cutoff was chosen on the basis of the root 
mean square deviation distribution in each group, picking the value corresponding to the first relative maximum 
in abscissa. The umbrella force constant was set to 4000 kJ/mol/nm2, and sampling of 100 ns was performed for 
each window. Umbrella sampling simulations were carried out at constant pressure using the Parrinello–Rah-
man  barostat64. Statistical errors of the PMFs were estimated using the Bayesian  bootstrap62 of complete histo-
grams (Supplementary Fig. S10), thereby considering only complete histograms as independent.
Free energy calculations of β-strand opening with different ligands and  Thr42 mutants. MD 
simulations were carried out on the N-SH2 domain (i) bound to either SPGEpYVNIEFGS ligand or to its trun-
cated form SPGEpYVNI, (ii) unbound either in its wild-type form or considering five possible mutants that 
have been studied  experimentally6, arising from a single-base change at codon 42. These mutations involved the 
substitution of the  Thr42 residue with Ala, Ser, Arg, Lys, or Ile. Starting from the wild-type structure, mutations 
were introduced with the Swiss-PdbViewer software package 4.165 and the rotamers were chosen based on (i) 
favorable contacts with the protein and (ii) potential energies. The AMBER99SB force field was used. The equi-
libration procedure was the same as for wild-type N-SH2 domain. Production runs were performed for 500 ns. 
The structures were further equilibrated with a closed central β-sheet by first applying a harmonic restraint and 
then a holonomic constraint on the hydrogen bond between  Gly39 and  Asn58, forming a β-strand, while two 
simulated tempering simulations of 10 ns each were performed. Then, pulling simulations were carried out for 
gradually opening the β-strand over 250 ns. As RC, we here used the distance between the carbonyl C atom of 
 Gly39 and the backbone N atom of  Asn58. The pull force constant was set to 1000 kJ/mol/nm2, whereas the refer-
ence  Gly39 C–Asn58 N distance between the β-strands was changed with a velocity of 5 × 10–6 nm/ps. Again, sim-
ulated  tempering57 was used to enhance sampling, using a temperature range from 300 to 380 K in steps of 10 K. 
The free energy profiles were obtained using umbrella sampling and  WHAM61,62. For each profile, 54 windows 
were used, the umbrella force constant was set to 1000 kJ/mol/nm2, and a sampling of 500 ns was performed for 
each window. Statistical errors of the PMFs were estimated with the Bayesian bootstrap of complete histograms, 
yielding a maximum error of less than 2 kJ/mol62.
Effects of  Thr42 substitutions on the propensity of N-SH2 for the α and β conformations. To 
test whether substitutions of  Thr42 modulate the propensity of N-SH2 for the α- and β-states, we computed the 
free energies for mutating  Thr42 with N-SH2 restrained to the α- or to β-state. These free-energy calculations 
were performed for the N-SH2 domain in its apo form or bound to the phosphopeptide SLNpYIDLDLVK. The 
restraint to α or β was again implemented with a restraint on a principal component (force constant 1000 kJ/
mol nm2)66. The free-energy calculations were carried out along an alchemical reaction coordinate λ.  Thr42 in 
wild type N-SH2 (λ = 0 state) was alchemically mutated to Ala, Ser, Arg, Lys and Ile, respectively (λ = 1 state), 
The AMBER99SB force field was used, and the topologies for the alchemical transformation were generated 
using  PMX67. The free energy difference was computed using Crooks Fluctuation  Theorem31,32,67. Following the 
protocol in Ref.67, each system was initially equilibrated, and slowly transformed from state λ = 0 to state λ = 1 
within 10 ns. Next, equilibrium simulations for every mutation were performed for 10 ns for the states λ = 0 and 
λ = 1. From every equilibrium trajectory, 200 fast nonequilibrium runs of 100 ps each were spawned morphing 
the system from λ = 0 to λ = 1, and other 200 from λ = 1 to λ = 0. A soft-core potential was used for Lennard–Jones 
and Coulomb  interactions68. The statistical error was estimated by bootstrapping (sampling with replacement) 
from the fast non-equilibrium runs.
Effects of peptide mutations on the affinity to the α- and β-states of N-SH2. To test if certain 
peptide mutations select for the α- or for the β-state of N-SH2, simulations were carried out on the N-SH2 
domain in solution bound to SLNpYIDLDLVK or SPGEpYVNIEFGS, while restraining N-SH2 in the α- or 
β-state with a harmonic restraint on a principal component (k = 1000 kJ/mol nm2). Every substitution, with the 
exception of proline, was applied on these two phosphopeptides at the sequence position + 5 and + 6 relative to 
phosphotyrosine. Free-energy calculations were performed using Crooks Theorem and the procedure reported 
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